Ourania  Tatsis net worth and biography

Ourania Tatsis Biography and Net Worth

Nia Tatsis, Ph.D., joined Vertex in 2017 and is the company’s Executive Vice President and Chief Regulatory and Quality Officer. In this role, she provides global regulatory leadership and is responsible for managing all regulatory interactions and quality assurance involving the research and development, manufacturing, and commercialization of Vertex’s transformational medicines. In addition to creating and executing the company’s global regulatory strategy, Dr. Tatsis also manages a worldwide team of regulatory professionals.

Prior to joining Vertex, Dr. Tatsis held positions of increasing responsibility at pharmaceutical companies such as Sanofi, Stemnion, Pfizer, and Wyeth. Most recently, she was Vice President, Head of Global Regulatory Affairs, at the Sanofi Genzyme Business Unit focused on Inflammation/Immunology, Rare Disease, Multiple Sclerosis, Ophthalmology, Neurology, and Oncology/Immuno-Oncology.

Dr. Tatsis also worked as an associate staff scientist and research fellow in Immunology and Vaccine Development at the Wistar Institute and completed a post-doctoral research fellowship in Immunology at Thomas Jefferson University. She received her Ph.D. in Cell and Molecular Biology from the University of Vermont and also holds a B.S. in Biology from Temple University.

What is Ourania Tatsis' net worth?

The estimated net worth of Ourania Tatsis is at least $17.03 million as of August 23rd, 2023. Dr. Tatsis owns 48,637 shares of Vertex Pharmaceuticals stock worth more than $17,030,246 as of December 9th. This net worth approximation does not reflect any other investments that Dr. Tatsis may own. Learn More about Ourania Tatsis' net worth.

How do I contact Ourania Tatsis?

The corporate mailing address for Dr. Tatsis and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at [email protected]. Learn More on Ourania Tatsis' contact information.

Has Ourania Tatsis been buying or selling shares of Vertex Pharmaceuticals?

Ourania Tatsis has not been actively trading shares of Vertex Pharmaceuticals in the last ninety days. Most recently, Ourania Tatsis sold 2,500 shares of the business's stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $355.00, for a transaction totalling $887,500.00. Following the completion of the sale, the executive vice president now directly owns 48,637 shares of the company's stock, valued at $17,266,135. Learn More on Ourania Tatsis' trading history.

Who are Vertex Pharmaceuticals' active insiders?

Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Vertex Pharmaceuticals?

During the last year, insiders at the pharmaceutical company sold shares 46 times. They sold a total of 172,832 shares worth more than $58,552,908.62. The most recent insider tranaction occured on November, 6th when Director Bruce I Sachs sold 11,250 shares worth more than $4,331,250.00. Insiders at Vertex Pharmaceuticals own 0.4% of the company. Learn More about insider trades at Vertex Pharmaceuticals.

Information on this page was last updated on 11/6/2023.

Ourania Tatsis Insider Trading History at Vertex Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/23/2023Sell2,500$355.00$887,500.0048,637View SEC Filing Icon  
2/27/2023Sell354$287.48$101,767.9256,805View SEC Filing Icon  
2/13/2023Sell275$298.99$82,222.2565,765View SEC Filing Icon  
8/9/2022Sell1,400$298.97$418,558.0046,090View SEC Filing Icon  
3/17/2022Sell2,833$250.11$708,561.63View SEC Filing Icon  
2/25/2022Sell325$230.95$75,058.75View SEC Filing Icon  
2/18/2022Sell519$231.00$119,889.00View SEC Filing Icon  
2/25/2020Sell1,296$233.17$302,188.3214,034View SEC Filing Icon  
2/18/2020Sell1,279$243.62$311,589.9816,349View SEC Filing Icon  
11/13/2019Sell2,853$205.59$586,548.2710,105View SEC Filing Icon  
10/1/2019Sell188$169.11$31,792.687,696View SEC Filing Icon  
See Full Table

Ourania Tatsis Buying and Selling Activity at Vertex Pharmaceuticals

This chart shows Ourania Tatsis's buying and selling at Vertex Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vertex Pharmaceuticals Company Overview

Vertex Pharmaceuticals logo
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $350.15
Low: $348.46
High: $354.35

50 Day Range

MA: $360.89
Low: $343.00
High: $385.76

2 Week Range

Now: $350.15
Low: $282.21
High: $387.42


1,394,568 shs

Average Volume

1,392,697 shs

Market Capitalization

$90.23 billion

P/E Ratio


Dividend Yield